AR

Aditya Rajagopal

CEO, Esperto Medical

Mountain View, California

Invests in

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Work Experience

  • CEO, Chairman, Co-Founder

    2018

    Caltech spin-out utilizing compressed sensing methods with ultrasound to continuously and non-invasively measure blood pressure. Backed by Maverick Ventures and others.

  • Founder & Chairman

    2012

    We are a multiplexed molecular diagnostics company with a bioinformatics focus and pedigree from Google[x], Illumina, Luminex, and Caltech. We are transforming the multi-billion dollar molecular diagnostics industry by democratizing personalized medicine. I am the Founder and Member of the Board of Directors of ChromaCode, and the inventor of core technologies related to combinatorics for biochemical labeling, multiplexed PCR assay design, and algorithms for data processing. Served as CTO from 2012 - 2024.

  • Chairperson

    2024

    Enabling dental offices with better patient diagnostics.

  • Independent Board Director

    2020

    Camena Bioscience utilizes novel "geometric synthesis" methods to build oligo nucleotides for synthetic biology with significantly higher length and purity. Advisor to Board of Directors and CEO (2020 - 2023) Independent Board Director (2023 - present)

2022

  • Advisor

    2022

2016

  • Visiting Associate (Visiting Faculty)

    2016

    I lead, fund, and manage a research group working on interesting things at the nexus of biology, medicine, and engineering. HDPCR (commercialized by ChromaCode) is the first technology to be transitioned into industry from our lab. Compressed sensing with ultrasound (commercialized by Esperto Medical) is the second.

  • Adjunct Assistant Professor, Biomedical Engineering

    2018

    I work on interesting problems related to fluorescence imaging methods.

2018 - 2024

  • Advisor

    2018 - 2024

    LunaPBC is the first community-owned health and DNA data platform dedicated to advancing research through community engagement, and personal data ownership, control and transparency. Founded by former executive leadership from Illumina and funded by Illumina Ventures and Arch Ventures. Serve as an advisor to the founders of the company.

2020 - 2022

  • Venture Partner

    2020 - 2022

    Investing at the nexus of data science, physical science, and life science. ND Capital investments include: Public: TWST, ARMO, SQZ Private: Visby, Inscripta

2018 - 2020

  • Visting Scholar, Canary Institute for Early Cancer Detection

    2018 - 2020